Spectrum Pharmaceuticals has appointed Kurt Gustafson as its executive VP, chief financial officer and principal accounting officer.
He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.
Prior to this role, he spent more than 18 years at Amgen, holding such positions as chief financial office of Amgen International and VP finance.
In addition to Gustafson’s appointment, Spectrum also announced that the company’s senior VP and acting chief financial officer Brett Scott has been appointed to the newly-created role of senior VP of finance.
Dr Rajesh Shrotriya, chairman, CEO and president of Spectrum, explained why the company had created the new role and appointed Gustafson.
“We believe this is a time of rapid growth at Spectrum, and the business is becoming more complex,” he said.
“Kurt brings in over 20 years of experience in finance and is a key addition to our already strong management team. We look forward to working with Kurt as we continue to build our business and execute our goals.”